Evidence map›Paper›PMID 42185926›Full record

ArticleTrials2026

Circulating tumor DNA-based assessment of disease progression after liver resection or transplantation for metastatic colorectal cancer or hepatocellular carcinoma-study protocol for a randomized, controlled trial.

I Górzyńska, O Kornasiewicz, A Koniczka, A Moskowicz, K Skubisz, J Pepłowski, A Lesiak, T Stokłosa, A Wójcicka, M Grąt

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07001085 (A Prospective Randomized Trial Assessing the Impact of ctDNA Testing in Patients After Liver Resection or Transplantation Due to Metastases From Colorectal Cancer or Hepatocellular Carcinoma), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07001085 narecruitingnot on this map

A Prospective Randomized Trial Assessing the Impact of ctDNA Testing in Patients After Liver Resection or Transplantation Due to Metastases From Colorectal Cancer or Hepatocellular Carcinoma (HCC) on Treatment Strategies and Long-term Survival"

TypeinterventionalSponsorMedical University of WarsawRan2025 to 2028Enrolled300ConditionsHCC - Hepatocellular Carcinoma, Colorectal Cancer MetastaticArmsTumor Tissue Collection and NGS, Blood Collection for Plasma ctDNA, ctDNA Mutation Analysis via ddPCR
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

I GórzyńskaDepartment of Tumor Biology and Genetics, Medical University of Warsaw, Warsaw, Poland.ORCID http://orcid.org/0009-0004-6201-7104
O KornasiewiczDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland. oskar.kornasiewicz@gmail.com.
A KoniczkaDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
A MoskowiczLaboratory of Genetics, University Clinical Centre of Medical University of Warsaw, Warsaw, Poland.
K SkubiszLaboratory of Genetics, University Clinical Centre of Medical University of Warsaw, Warsaw, Poland.
J PepłowskiLaboratory of Genetics, University Clinical Centre of Medical University of Warsaw, Warsaw, Poland.
A LesiakLaboratory of Genetics, University Clinical Centre of Medical University of Warsaw, Warsaw, Poland.
T StokłosaDepartment of Tumor Biology and Genetics, Medical University of Warsaw, Warsaw, Poland.
A WójcickaKnow More Foundation, Warsaw, Poland.
M GrątDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Funding

Agencja Badań Medycznych 2023/ABM/01/00068
6 · The paper itself

Abstract

BACKGROUND/

aimHepatocellular carcinoma (HCC) and colorectal cancer liver metastases (CRLM) carry high recurrence rates after surgery or transplantation. Conventional imaging and biomarkers have limited sensitivity for detecting minimal residual disease (MRD). Circulating tumor DNA (ctDNA) is a promising biomarker that may enable earlier recurrence detection compared with standard methods. The aim of this randomized controlled trial is to evaluate the clinical utility of ctDNA monitoring in the early detection of disease recurrence and its impact on monitoring progression in patients undergoing liver resection or transplantation for HCC and CRLM.

methodsThis randomized, controlled trial will enroll 300 patients undergoing liver resection or transplantation for CRLM or HCC. Participants will be randomized 2:1 to ctDNA monitoring or standard follow-up. ctDNA will be analyzed at three predefined time points (baseline, 1 month, and 6 months postoperatively) and compared with tumor tissue mutation profiles generated by next-generation sequencing (NGS). All patients will be followed for 24 months with imaging, tumor markers, and quality-of-life assessments. The primary endpoint is ctDNA-defined recurrence. Secondary endpoints include recurrence-free survival, overall survival, time to recurrence detection, patient-reported outcomes, and cost-effectiveness. DISCUSSION: This study will assess whether ctDNA-guided monitoring enables earlier recurrence detection and improves clinical decision-making after liver resection or transplantation. Incorporating ctDNA into surveillance may support earlier therapeutic intervention, optimize follow-up strategies, and enhance long-term outcomes.

trial registrationClinicalTrials.gov NCT07001085. Registered on 2025.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularCirculating Tumor DNAColorectal NeoplasmsHepatectomyLiver NeoplasmsLiver TransplantationDisease ProgressionHumansNeoplasm Recurrence, LocalNeoplasm, ResidualPredictive Value of TestsRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeBiomarkers, TumorCirculating Tumor DNABiomarkersCirculating tumor DNAColorectal cancerHepatocellular carcinoma

Identifiers

PMID42185926
PMCPMC13386887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.